ArticleAmerican journal of clinical and experimental immunology2025
Cyclophosphamide modulates Wnt3a/β-catenin signaling in MRL/lpr mice with lupus nephritis.
Article in American journal of clinical and experimental immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was carried out to analyze the time-dependent changes of Wnt3a/β-catenin signaling during lupus nephritis (LN). At the age of 5 weeks, 30 female MRL/lpr mice and C57BL/6 (C57) mice were randomly grouped. Moreover, 12 females MRL/lpr mice were split into two groups, cyclophosphamide treatment (LN-CTX) and one was untreated. Mice in the LN-CTX group were injected intraperitoneally with cyclophosphamide (CTX) from the age of 16 wk. Urinary protein, serum antinuclear antibodies (ANA), and anti-double-stranded DNA (dsDNA) antibody levels were measured. The detection of renal injury was later confirmed through histopathology, and immunofluorescence analysis. Compared with C57 mice, LN mice had much higher levels of 24-hour urinary protein, ANA and dsDNA antibodies (P<0.05). Histological examination exhibited the proliferation of mesangial cells with the invasion of inflammatory cells, while deposition of immune complex was shown to reach the peak at 28 weeks. The production of Wnt3a and β-catenin proteins and mRNA was significantly increased in the kidneys of LN mice. In contrast, 24-hour urinary protein, ANA and dsDNA antibodies levels decreased significantly and CTX treatment caused a drop in the aforementioned immune response (P<0.05). Renal histopathological changes and immune complex deposition were ameliorated by CTX treatment. the renal levels. Notably, the renal levels of Wnt3a/β-catenin at LN-CTX were found to be lower than that in the untreated LN group. The abnormal activation of the Wnt/β-catenin signaling pathway may play a role in LN formation and thus important molecular target for CTX drug. This research shows that CTX inhibits renal Wnt3a/β-catenin activation in LN mice for the first time, offering a potential molecular mechanism for its renoprotective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.